Evidence

Review and download supporting evidence. Includes the full guideline if available.

Supporting evidence

Surveillance report
2024 exceptional surveillance of suspected cancer: recognition and referral (NICE guideline NG12)
2024 exceptional surveillance of suspected cancer: recognition and referral (NICE guideline NG12) and suspected neurological conditions: recognition and referral (NICE guideline NG127)
2022 exceptional surveillance of suspected cancer: recognition and referral (NICE guideline NG12) and quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care (NICE diagnostics guidance 30)
Appendix A: Summary of evidence from surveillance ^{PDF 432 KB} 30 June 2022
Appendix B: Stakeholder consultation comments table ^{PDF 850 KB} 30 June 2022
2021 exceptional surveillance of suspected cancer: recognition and referral (NICE guideline NG12) and suspected neurological conditions: recognition and referral (NICE guideline NG127)
2021 exceptional surveillance of suspected cancer: recognition and referral (NICE guideline NG12)
2020 Surveillance of suspected cancer: recognition and referral (NICE guideline NG12)
Appendix A: Summary of evidence from surveillance ^{PDF 884 KB} 31 January 2020
Appendix B: Stakeholder consultation comments table ^{PDF 1.21 MB} 31 January 2020
Evidence review
Evidence review - December 2021
A: Diagnostic accuracy of prostate specific antigen (PSA) thresholds for referring people with suspected prostate cancer ^{PDF 2.28 MB} 15 December 2021
Full guidance
Appendices A–E ^{PDF 788 KB} 11 September 2020
Appendix F ^{PDF 16.88 MB} 11 September 2020
Appendix G ^{PDF 2.52 MB} 11 September 2020
Appendix H ^{PDF 1.61 MB} 11 September 2020
Appendix I ^{PDF 353 KB} 11 September 2020
Appendix J1 ^{PDF 6.1 MB} 11 September 2020
Appendix J2 ^{PDF 3.52 MB} 11 September 2020
Appendix J3 ^{PDF 514 KB} 11 September 2020
Appendix J4 ^{PDF 580 KB} 11 September 2020
Full guideline ^{PDF 4.1 MB} 11 September 2020